Skip main navigation

Biopta collaborates with Merck to investigate in vivo cardiac effects

13 November 2013

In a recent collaboration with Merck, Biopta conducted human functional tissue experiments to investigate the mechanisms underlying two anti-arrhythmic drugs. Hemodynamic effects are often noted as adverse events with the use of antiarrhythmic drugs, including those used for the treatment of atrial fibrillation. To read a paper which explores the intrinsic vasorelaxant and inotropic effects of vernakalant and flecainide in isolated human subcutaneous resistance artery and in ventricular trabecular muscle preparations click the following link:

https://journals.lww.com/cardiovascularpharm/Abstract/2013/03000/Comparison_of_the_Intrinsic_Vasorelaxant_and.8.aspx

The functional human tissue experiments described in this paper were all conducted by Biopta Ltd at their GLP laboratory in Glasgow, UK.

Subscribe to receive updates